Can U.S. Policy Bring Generic Drug Manufacturing Back Home?
By Katie Anderson, Chief Editor, Pharmaceutical Online
The U.S. pharmaceutical industry is on the cusp of change, as large manufacturers pledge billions of dollars and break ground on domestic facilities to produce drug products and APIs. But will those investments strengthen the supply chain, and what will they mean for the generic medicines that account for 90% of prescriptions in the U.S.?
Rising Costs for Generic Imports
Generic medicines imported into the U.S. were not subject to the recently imposed tariffs on imported pharmaceuticals, but President Trump posted in July that this could change within two years. According to the post, generic imports would face a 100% tariff in the first year of the policy and a 200% tariff the year after.
Tariffs are only one part of the policy pressure building around pharmaceutical supply chains. FDA user-fee negotiations are also beginning to reflect a preference for domestic manufacturing capacity, especially when U.S.-made finished dosage forms are paired with U.S.-produced APIs.
The FDA is also following suit with the White House’s initiative to prioritize U.S. made generic medicine. The FDA has issued a new Generic Drug User Fee Amendments (GDUFA) commitment letter for 2028-2032. GDUFA IV includes a $10,000 increase in the foreign facility differential, from $15,000 to $25,000 to cover increasing costs for inspecting foreign facilities.
Other Generic Policy Changes
The FDA has suggested a one-time waiver for domestically produced drugs, if the API is also produced in the U.S. It is also proposed that Priority ANDA review be amended to center around U.S-produced drug product, U.S.-produced API and U.S. based bioequivalence testing.
Though the global small molecule API market is growing 4.5% annually to reach $278.6 billion in 2033, reports differ on just home much of the API used in U.S.-consumed medicines are produced stateside. What is evident, though, is that producing more API and drug product in the United States requires not only a heavy investment in infrastructure, but also a heavy investment in process technology. With tight margins for profit, generic manufacturers must be wise in placing that investment. In a past interview with Kevin Webb from the API Innovation Center, he highlighted that there is government assistance available for this investment.
The FDA also proposed that before submitting an ANDA, a U.S. facility can request a faster inspection to streamline approval. There is a public meeting on Sept. 17, 2026, and the current GDUFA expires in Sept. 2027.
A Work In Progress
The central question is whether these incentives can shift more API and generic drug product production back to the United States without destabilizing access to affordable medicines. The technology may be available, and policy momentum is building, but the economics remain unresolved. For generic manufacturers, the path back home will depend on whether federal incentives can offset the cost of building, qualifying, inspecting, and sustaining domestic capacity at prices the market can bear.